Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;70(3):e30173.
doi: 10.1002/pbc.30173. Epub 2022 Dec 29.

Pediatric refractory immune thrombocytopenia: A systematic review

Layan Ibrahim  1 , Selina X Dong  2 , Katie O'Hearn  3 , Amanda B Grimes  4 , Shipra Kaicker  5 , Stephanie FritchLilla  6 , Vicky R Breakey  7 , Rachael F Grace  8 , Jeffrey D Lebensburger  9 , Robert J Klaassen  3 , Michele Lambert  10   11
Affiliations

Pediatric refractory immune thrombocytopenia: A systematic review

Layan Ibrahim et al. Pediatr Blood Cancer. 2023 Mar.

Abstract

Pediatric immune thrombocytopenia (ITP) is an acquired disorder associated with autoimmune destruction and impairment of platelet production in children. Some children exhibit poor or transient response to ITP-directed treatments and are referred to as having refractory ITP (rITP). There is currently no consensus on the definition of rITP, nor evidence-based treatment guidelines for patients with rITP. After a survey of pediatric ITP experts demonstrated lack of consensus on pediatric rITP, we pursued a systematic review to examine the reported clinical phenotypes and treatment outcomes in pediatric rITP. The search identified 253 relevant manuscripts; following review, 11 studies proposed a definition for pediatric rITP with no consensus amongst them. Most definitions included suboptimal response to medical management, while some outlined specific platelet thresholds to define this suboptimal response. Common attributes identified in this study should be used to propose a comprehensive definition, which will facilitate outcome comparisons of future rITP studies.

Keywords: child; idiopathic; purpura; systematic review; thrombocytopenic; treatment failure; treatment outcome.

PubMed Disclaimer

References

REFERENCES

    1. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866. https://doi.org/10.1182/BLOODADVANCES.2019000966
    1. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3(22):3780-3817. https://doi.org/10.1182/BLOODADVANCES.2019000812
    1. Jayabose S, Levendoglu-Tugal O, Ozkaynkak MF, Visintainer P, Sandoval C. Long-term outcome of chronic idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol. 2004;26(11):724-726. https://doi.org/10.1097/00043426-200411000-00007
    1. Terrell DR, Neunert CE, Cooper N, et al. Immune thrombocytopenia (ITP): current limitations in patient management. Medicina (Kaunas). 2020;56(12):667. https://doi.org/10.3390/MEDICINA56120667
    1. Djulbegovic B, Cohen Y, Portielje JEA, Westendorp RGJ, Kluin-Nelemans HC, Brand A. The natural history of refractory idiopathic thrombocytopenic purpura. Blood. 2001;98(7):2282-2283. https://doi.org/10.1182/BLOOD.V98.7.2282

Publication types

LinkOut - more resources